OSE Immunotherapeutics SA (EPA:OSE)
3.176
-0.030 (-0.94%)
Aug 3, 2026, 5:22 PM CET
OSE Immunotherapeutics Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 17.55 | 16.75 | 18.67 | 25.62 | 33.58 |
Short-Term Investments | 14.12 | 49.05 | 10.82 | - | 9.85 |
Cash & Short-Term Investments | 31.68 | 65.79 | 29.5 | 25.62 | 43.43 |
Cash Growth | -51.86% | 123.06% | 15.13% | -41.01% | 12.06% |
Accounts Receivable | 0.31 | 4.14 | 0.98 | 0.4 | - |
Other Receivables | - | - | - | - | 0.77 |
Total Trade Receivables | 0.31 | 4.14 | 0.98 | 0.4 | 0.77 |
Other Current Assets | - | - | - | 11.18 | - |
Total Current Assets | 31.99 | 69.93 | 30.48 | 37.2 | 44.21 |
Net Property, Plant & Equipment | 3.68 | 3.43 | 4.07 | 4.98 | 49.65 |
Other Intangible Assets | 41.54 | 44.01 | 46.4 | 48.78 | 108.79 |
Long-Term Investments | 1.46 | 6.4 | 0.91 | 0.64 | 0.94 |
Other Long-Term Assets | 0.19 | 0.19 | 0.2 | 0.18 | 0.17 |
Total Assets | 78.86 | 123.96 | 82.05 | 91.78 | 101.88 |
Accounts Payable | 8.82 | 7.72 | 9.3 | 8.54 | 9.61 |
Accrued Expenses | 1.2 | 2.04 | 0.35 | 0.82 | 1.05 |
Short-Term Debt | 9.97 | 7.2 | 6.4 | 3.09 | 1.61 |
Current Portion of Leases | 0.77 | 0.6 | 0.86 | 0.88 | 0.76 |
Other Current Liabilities | 3.22 | 2.67 | 1.89 | 2.94 | 3.74 |
Total Current Liabilities | 24.9 | 20.22 | 18.8 | 16.27 | 16.76 |
Long-Term Debt | 21.83 | 35.66 | 35.51 | 37.23 | 30.8 |
Long-Term Leases | 2.81 | 2.68 | 3.03 | 3.59 | 3.97 |
Other Long-Term Liabilities | 1.56 | 1.59 | 1.74 | 2.04 | 2.46 |
Total Long-Term Liabilities | 26.2 | 39.93 | 40.28 | 42.86 | 37.22 |
Total Liabilities | 51.1 | 60.15 | 59.08 | 59.12 | 53.99 |
Common Stock | 4.49 | 4.39 | 4.33 | 3.71 | 3.71 |
Treasury Stock | -0.34 | -0.45 | -0.41 | -0.55 | -0.16 |
Additional Paid-in Capital | 77.71 | 77.74 | 76.64 | 65.61 | 65.61 |
Retained Earnings | -54.11 | -17.87 | -57.59 | -36.11 | -21.26 |
Shareholders' Equity | 27.76 | 63.81 | 22.98 | 32.66 | 47.89 |
Total Liabilities & Equity | 78.86 | 123.96 | 82.05 | 91.78 | 101.88 |
Total Debt | 35.38 | 46.13 | 45.8 | 44.79 | 37.13 |
Net Cash (Debt) | -3.7 | 19.66 | -16.31 | -19.17 | 6.3 |
Net Cash Growth | - | - | - | - | -67.26% |
Net Cash Per Share | -0.17 | 0.90 | -0.83 | -1.03 | 0.35 |
Book Value | 27.76 | 63.81 | 22.98 | 32.66 | 47.89 |
Book Value Per Share | 1.25 | 2.93 | 1.17 | 1.76 | 2.64 |
Tangible Book Value | -13.79 | 19.8 | -23.43 | -16.13 | -60.9 |
Tangible Book Value Per Share | -0.62 | 0.91 | -1.20 | -0.87 | -3.35 |